282 related articles for article (PubMed ID: 30389701)
1. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.
Allen-Petersen BL; Risom T; Feng Z; Wang Z; Jenny ZP; Thoma MC; Pelz KR; Morton JP; Sansom OJ; Lopez CD; Sheppard B; Christensen DJ; Ohlmeyer M; Narla G; Sears RC
Cancer Res; 2019 Jan; 79(1):209-219. PubMed ID: 30389701
[TBL] [Abstract][Full Text] [Related]
2. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
3. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR; Sun SY
J Biol Chem; 2013 May; 288(19):13215-24. PubMed ID: 23536185
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of cell proliferation and induction of apoptosis in pancreatic ductal adenocarcinoma cells by verrucarin A, a macrocyclic trichothecene, is associated with the inhibition of Akt/NF-кB/mTOR prosurvival signaling.
Deeb D; Gao X; Liu Y; Zhang Y; Shaw J; Valeriote FA; Gautam SC
Int J Oncol; 2016 Sep; 49(3):1139-47. PubMed ID: 27573873
[TBL] [Abstract][Full Text] [Related]
5. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
Soares HP; Ni Y; Kisfalvi K; Sinnett-Smith J; Rozengurt E
PLoS One; 2013; 8(2):e57289. PubMed ID: 23437362
[TBL] [Abstract][Full Text] [Related]
6. UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism.
Dando I; Pacchiana R; Pozza ED; Cataldo I; Bruno S; Conti P; Cordani M; Grimaldi A; Butera G; Caraglia M; Scarpa A; Palmieri M; Donadelli M
Free Radic Biol Med; 2017 Dec; 113():176-189. PubMed ID: 28962872
[TBL] [Abstract][Full Text] [Related]
7. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
8. (+)-Cyanidan-3-ol inhibits epidermoid squamous cell carcinoma growth via inhibiting AKT/mTOR signaling through modulating CIP2A-PP2A axis.
Monga J; Suthar SK; Rohila D; Joseph A; Chauhan CS; Sharma M
Phytomedicine; 2022 Jul; 101():154116. PubMed ID: 35525235
[TBL] [Abstract][Full Text] [Related]
9. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
10. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.
Umesalma S; Kaemmer CA; Kohlmeyer JL; Letney B; Schab AM; Reilly JA; Sheehy RM; Hagen J; Tiwari N; Zhan F; Leidinger MR; O'Dorisio TM; Dillon J; Merrill RA; Meyerholz DK; Perl AL; Brown BJ; Braun TA; Scott AT; Ginader T; Taghiyev AF; Zamba GK; Howe JR; Strack S; Bellizzi AM; Narla G; Darbro BW; Quelle FW; Quelle DE
J Clin Invest; 2019 Mar; 129(4):1641-1653. PubMed ID: 30721156
[TBL] [Abstract][Full Text] [Related]
11. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
12. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
Farrington CC; Yuan E; Mazhar S; Izadmehr S; Hurst L; Allen-Petersen BL; Janghorban M; Chung E; Wolczanski G; Galsky M; Sears R; Sangodkar J; Narla G
J Biol Chem; 2020 Jan; 295(3):757-770. PubMed ID: 31822503
[TBL] [Abstract][Full Text] [Related]
13. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O; O'Connor CM; Kulesskiy E; Sangodkar J; Aakula A; Izadmehr S; Yetukuri L; Yadav B; Padzik A; Laajala TD; Haapaniemi P; Momeny M; Varila T; Ohlmeyer M; Aittokallio T; Wennerberg K; Narla G; Westermarck J
Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021885
[TBL] [Abstract][Full Text] [Related]
14. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
15. Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer.
Tasaki Y; Suzuki M; Katsushima K; Shinjo K; Iijima K; Murofushi Y; Naiki-Ito A; Hayashi K; Qiu C; Takahashi A; Tanaka Y; Kawaguchi T; Sugawara M; Kataoka T; Naito M; Miyata K; Kataoka K; Noda T; Gao W; Kataoka H; Takahashi S; Kimura K; Kondo Y
Cancer Res; 2021 Apr; 81(7):1654-1666. PubMed ID: 33648930
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
[TBL] [Abstract][Full Text] [Related]
17. Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC.
Wu L; Yi B; Wei S; Rao D; He Y; Naik G; Bae S; Liu XM; Yang WH; Sonpavde G; Liu R; Wang L
Cancer Res; 2019 Apr; 79(7):1413-1425. PubMed ID: 30733194
[TBL] [Abstract][Full Text] [Related]
18. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
19. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
20. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
